PTC/SB/08s (08-03)
Approved for use through 97/31/2006. OMB 0651-0031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unfees it contains a valid OMB control number.

U.S. Patient and Trademark Office; U.S. Defact for use through 07/31/2006, OMB 0651-00

U.S. Patient and Trademark Office; U.S. DEPARTIENT OF COMMER

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unies at contains a valid OMB control numb

	Application Number			
NEODIATION DIOCI COURT	Filing Date			
INFORMATION DISCLOSURE	First Named Inventor Yoshi		ito Katano	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit			
(Not for Submission and of or it iso)	Examiner Name			
	Attorney Docket Numb	er	09792909-6735	

					U.S.	PATENTS			Remove	
Examiner Initial*	er Cite No Patent Number Kind Code1 Issue Date Name of Patentee or App			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear						
	1	6546517		2003-0	4-08	Yoshimura				
If you wish	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*			Name of Patentee of Applicant Re		Relev	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1									
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d buttor		
				FOREIG	SN PAT	TENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	74
	1	10-011293	JP			1998-01-16	NEC Corp			
	2	2003-271391	JP			2003-09-26	Samsung Electron Ltd	ics Co		
	3	07-098659	JP			1995-04-11	TEC Corp			

	4	2001	1-027953	JP		2001-01-30	Mitsubishi Electric Corp		_
	5	05-2	65767	JP		1993-10-15	NEC Corp		
	6	57-0	71508	JP		1982-05-04	NEC Corp		
If you wis	h to a	dd add	ditional Foreign Pa	atent Document	citation	information pl	ease click the Add butto	Add	
	NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner Initials*	miner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, dry and/or country where published.							T5	
	1 International Search Report dated March 1, 2005								
If you wish to add additional non-patent literature document citation information please click the Add button Add									
EXAMINER SIGNATURE									
Examiner Signature Date Considered									
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a									

1 See Kinz Codes of USPTO Potent Documents at twent_USET_LOCU/or MEPE 981.64. 2 Enter often that issued the document, by the two-lets of (MPD Standard 513.) 2 "For Jumpines patient outcomests, the collection of the year of the register that precise the certain protect the seal manufacture. 4 "Kind of document by the appropriate symbols as addicated on the document under WIPO Standard 51.16 if possible. 2 Applicant is to place a check mark here if English targinguise thresistors is addicated.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Application Number Filing Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 199) Application Number Filing Date First Named Inventor Yoshito Katano Art Unit Examiner Name Attorney Docket Number | 09792009-6735

CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement, See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 179(10).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

□ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/David R. Metzger/	Date (YYYY-MM-DD)	2006-07-21
Name/Print	David R. Metzger	Registration Number	32919

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademán / Office, U.S. Operatment of Commence, P. 0. Bot 1450, Alexandria, V.3.231.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, V.3.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.